Azusa Nagai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Azusa Nagai has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ichiro Yabe
Department of Neurology, Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo Japan
2 shared publications - Masahiro Wakita
Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, N15, W7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan
2 shared publications - Hideki Houzen
Department of Neurology, Obihiro Kosei Hospital, Obihiro 080-0024, Hokkaido, Japan
1 shared publication - Hiroyuki Kameda
Department of Diagnostic and Interventional Radiology, Hokkaido University Hospital, Sapporo, Japan
1 shared publication - Hiroyuki Sugimori
Department of Biomedical Science and Engineering, Faculty of Health Sciences, Hokkaido University, Sapporo 060-0812, Japan
1 shared publication - Ichiro Kusumi
Department of Psychiatry Hokkaido University Graduate School of Medicine Sapporo Japan
1 shared publication
Latest Publications
- 1 April 2022
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 87, 77-85
Quantitative magnetic resonance imaging for evaluating of the cerebrospinal fluid kinetics with 17O-labeled water tracer: A preliminary report
- 1 April 2022
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 87, 77-85
Quantitative magnetic resonance imaging for evaluating of the cerebrospinal fluid kinetics with 17O-labeled water tracer: A preliminary report
- Open Access
- 21 July 2021
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (8) , 705
Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan
Reports on the long-term survival effect of edaravone, which was approved for the treatment of amyotrophic lateral sclerosis (ALS) in 2015 in Japan, are rare. Herein, we report our retrospective analysis of 45 consecutive patients with ALS who initially visited our hospital between 2013 and 2018. Of these, 22 patients were treated with edaravone for an average duration of 26.6 (range, 2–64) months, whereas the remaining patients were not treated with edaravone and comprised the control group. There were no differences in baseline demographics between the two groups. The primary endpoint was tracheostomy positive-pressure ventilation (TPPV) or death, and the follow-up period ended in December 2020. The survival rate was significantly better in the edaravone group than in the control group based on the Kaplan–Meier analysis, which revealed that the median survival durations were 49 (9–88) and 25 (8–41) months in the edaravone and control groups, respectively (p = 0.001, log-rank test). There were no serious edaravone-associated adverse effects during the study period. Overall, the findings of this single-center retrospective study suggest that edaravone might prolong survival in patients with ALS.
- 21 July 2021
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (8) , 705
Open AccessImproved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan
Reports on the long-term survival effect of edaravone, which was approved for the treatment of amyotrophic lateral sclerosis (ALS) in 2015 in Japan, are rare. Herein, we report our retrospective analysis of 45 consecutive patients with ALS who initially visited our hospital between 2013 and 2018. Of these, 22 patients were treated with edaravone for an average duration of 26.6 (range, 2–64) months, whereas the remaining patients were not treated with edaravone and comprised the control group. There were no differences in baseline demographics between the two groups. The primary endpoint was tracheostomy positive-pressure ventilation (TPPV) or death, and the follow-up period ended in December 2020. The survival rate was significantly better in the edaravone group than in the control group based on the Kaplan–Meier analysis, which revealed that the median survival durations were 49 (9–88) and 25 (8–41) months in the edaravone and control groups, respectively (p = 0.001, log-rank test). There were no serious edaravone-associated adverse effects during the study period. Overall, the findings of this single-center retrospective study suggest that edaravone might prolong survival in patients with ALS.